Table 1 Baseline characteristics of GD patients
Numbers (%) | GD no relapse | GD relapse | P - value§ |
|---|---|---|---|
Sex | 65 (49.6%) | 18 (13.7%) | |
Female | 55 (85%) | 15 (83%) | 0.89 |
Male | 10 (15%) | 3 (17%) | |
Age (years), mean ± SD | 52 ± 13 | 47 ± 13 | 0.13 |
BMI (kg/m2), mean ± SD | 24 ± 4.6 | 25 ± 3.7 | 0.23 |
Smokers | 9 (25%) | 1 (20%) | 0.81 |
Treatment duration (months), median (IQR) | 19 (18, 21) | 18 (17, 21) | 0.81 |
Follow up duration after ATD stop (months), median (IQR) | 11 (3, 36) | 1 (0.5, 11) | < 0.01 |
Thyroid volume (ml), median (IQR) | 14 (11, 18) | 14 (9.6, 16) | 0.71 |
Goiter size (WHO grade, 0-III) | |||
0 | 33 (62%) | 10 (67%) | 0.84 |
I | 12 (23%) | 4 (27%) | |
II | 7 (13%) | 1 (7%) | |
III | 1 (2%) | 0 (0%) | |
Endocrine orbitopathy (N/%) | 18 (28%) | 7 (39%) | 0.36 |
fT4 (pM), median (IQR) | 30 (21, 36) | 35 (20, 55) | 0.31 |
T3 (pM), median (IQR) | 3.5 (2.5, 4.4) | 2.9 (2.5, 6.4) | 0.90 |
fT3 (pM), median (IQR) | 10 (7.7, 17) | 21 (14, 29) | 0.06 |
TPO-Ab (U/l), median (IQR) | 89 (49, 475) | 120 (90, 357) | 0.49 |
Routine TRAb assaya (U/L), median (IQR) | 5.4 (2.8, 10) | 12 (3.5, 27) | 0.10 |
IMMULITE TSI (Cut-off 0.55 U/L), median (IQR) | 3.4 (1.6, 7.5) | 5.6 (3.6, 17) | 0.04 |
BRAHMS TRAK (Cut-off 1.8 U/L), median (IQR) | 4.6 (2.6, 11) | 8.6 (5.1, 20) | 0.02 |
EliA anti-TSH-R (Cut-off 2.9 U/L), median (IQR) | 4.4 (2.9, 9.6) | 7.4 (4.4, 13) | 0.04 |
RSR TRAb Fast (Cut-off 1.0 U/L), median (IQR) | 4.3 (2.7, 7.5) | 6.9 (4.1, 16) | 0.06 |
RSR-bioassay STIMULATION (Cut-off 150%), median (IQR) | 461 (192, 835) | 536 (291, 1419) | 0.26 |
Additional autoimmune disease: | 0.51 | ||
GIT (IBD, CD, pernicious anemia) | 1 | 1 | |
T1DM | 1 | 0 | |
Other | 1 | 0 | |